Immatics N.V(IMTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.85 | Insider Own | 14.65% | Shs Outstand | 136.7M | Perf Week | -3.05% |
| Market Cap | 1.09B | Forward P/E | - | EPS next Y | -3.01% | Insider Trans | 4.1% | Shs Float | 127.7M | Perf Month | -16.74% |
| Enterprise Value | 0.66B | PEG | - | EPS next Q | -0.5 | Inst Own | 65.02% | Short Float | 2.93% | Perf Quarter | -15.59% |
| Income | -0.24B | P/S | 22.51 | EPS this Y | -12.01% | Inst Trans | -4.33% | Short Ratio | 4.76 | Perf Half Y | -33.48% |
| Sales | 0.05B | P/B | 2.19 | EPS next 5Y | -0.22% | ROA | -39.45% | Short Interest | 3.75M | Perf YTD | -30.38% |
| Book/sh | 3.34 | P/C | 2.43 | EPS past 3/5Y | - 18.43% | ROE | -48.08% | 52W High | -41.1% ($12.41) | Perf Year | -29.3% |
| Cash/sh | 3.01 | P/FCF | - | Sales past 3/5Y | -33.07% 8.86% | ROIC | -51.2% | 52W Low | 9.92% ($6.65) | Perf 3Y | -3.18% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -164.71% | Gross Margin | - | Volatility(W/M) | 5.58% 6.19% | Perf 5Y | -48.99% |
| Dividend TTM | - | EV/Sales | 13.6 | Sales Y/Y TTM | -65.4% | Oper. Margin | -555.6% | ATR (14) | 0.43 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.54 | EPS Q/Q | 18.96% | Profit Margin | -495.72% | RSI (14) | 43.39 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.54 | Sales Q/Q | 98.02% | SMA20 | 0.03% ($7.31) | Beta | 1.35 | Target Price | $16.31 |
| Payout | - | Debt/Eq | 0.04 | Earnings | 2026/8/18 | SMA50 | -11.68% ($8.28) | Rel Volume | 1.5 | Prev Close | $7.35 |
| Employees | 407 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | -10.59% 0.78% | SMA200 | -23.87% ($9.6) | Avg Volume(3M) | 0.79M | Price | $7.31 |
| IPO | 2018/12/12 | Option/Short | Yes/Yes | Trades | 8409 | Volume | 1,178,962 | Change | -0.54% |
🧬 Immatics is a clinical-stage biotech company developing T-cell receptor (TCR)-based immuno-oncology therapies. It maintains a broad pipeline of cell therapies that precisely target PRAME antigens as well as TCR bispecific antibodies, pursuing differentiated targeting strategies in the solid tumor space.
Over the past 1 year, on the lower side
41% below its 1-year high.
Traded more than usual. That is 150% of its average volume.
IMTX has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -12.0% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,251. Peers typically go for $1,217.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -49.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 65.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #151 of 594 in the industry
Based on market cap of $1B.
FAQ
What kind of company is IMTX?
IMTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IMTX?
The market cap of IMTX is approximately $1.1B, ranking 2,522 within its sector.
What is the 52-week high and low for IMTX?
IMTX has recorded a 52-week high of $12.41 and a low of $6.65.
